Clinical Trials
22 trialsNCT06977737 2026-05-22
ATTEST
Accession Therapeutics Limited
Phase 1/2 Recruiting
NCT06144671 2026-04-27
GT201 Injection For The Treatment Of Advanced Solid Tumors
Grit Biotechnology
Phase 1/2 Recruiting
NCT04219254 2026-04-15
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
BioInvent International AB
Phase 1/2 Recruiting
NCT06554795 2026-03-27
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1/2 Recruiting
NCT05689853 2026-03-18
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
Akeso
Phase 1/2 Recruiting
NCT04725474 2026-01-12
GDFATHER
CatalYm GmbH
Phase 1/2 Active not recruiting
NCT06265727 2026-01-08
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
Corbus Pharmaceuticals Inc.
Phase 1/2 Recruiting
NCT05307874 2025-12-24
EVICTION-2
ImCheck Therapeutics
Phase 1/2 Completed
NCT06088004 2025-08-22
Phase â… /â…¡ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors
Suzhou Abogen Biosciences Co., Ltd.
Phase 1/2 Recruiting
NCT05435339 2025-04-22
A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy
Genmab
Phase 1/2 Terminated
NCT06895733 2025-03-26
Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)
Tianjin Medical University Second Hospital
Phase 1/2 Recruiting
NCT04585035 2025-03-18
Study to Evaluate D-1553 in Subjects With Solid Tumors
InventisBio Co., Ltd
Phase 1/2 Active not recruiting
NCT04597541 2025-03-10
A Study of AK112 for Advanced Solid Tumors
Akeso
Phase 1/2 Completed
NCT05559541 2025-02-19
Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors
Akeso
Phase 1/2 Terminated
NCT06524804 2024-12-18
A Phase Ib/II Study of BY101298 , an Oral DNA-PK Inhibitor, Combined with Radiotherapy in Patients with Malignant Solid Tumors
Chengdu Baiyu Pharmaceutical Co., Ltd.
Phase 1/2 Terminated
NCT04020185 2024-12-11
Safety and Efficacy Study of IMSA101 in Refractory Malignancies
ImmuneSensor Therapeutics Inc.
Phase 1/2 Completed
NCT06622486 2024-11-07
First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors
Egle Therapeutics
Phase 1/2 Recruiting
NCT04121442 2024-08-06
Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors
Buzzard Pharmaceuticals
Phase 1/2 Completed
NCT04092673 2024-05-21
Zotatifin
Effector Therapeutics
Phase 1/2 Recruiting
NCT06056323 2023-10-23
A Study of HB0045 Injection in Patients With Advanced Solid Tumors
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 1/2 Unknown
NCT03160833 2020-02-13
A Study of HMPL-453 in Patients With Advanced Solid Malignancies
Hutchmed
Phase 1/2 Unknown
NCT03030001 2017-01-24
PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies
Ningbo Cancer Hospital
Phase 1/2 Unknown